Ignite Creation Date:
2024-05-06 @ 7:11 PM
Last Modification Date:
2024-10-26 @ 3:02 PM
Study NCT ID:
NCT05924620
Status:
COMPLETED
Last Update Posted:
2024-06-18
First Post:
2023-06-21
Brief Title:
Efficacy and Safety of Finerenone in Patients With Primary Aldosteronism
Sponsor:
Chongqing Medical University
Organization:
Chongqing Medical University
Study Overview
Official Title:
Efficacy and Safety of Finerenone in Patients With Primary Aldosteronism a Randomized Controlled Trial
Status:
COMPLETED
Status Verified Date:
2023-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To study the efficacy and safety of finerenone in patients with primary aldosteronism
Detailed Description:
This is a prospective and randomized study involving patients with primary aldosteronismPA All paticipants will be randomized into finerenone groupIntervention group and spironolactone groupControl group and to compare the antihypertensive effect in patients with PA
If the self-measured blood pressure of patients at home continues to be greater than 14090 mmHg at 2-4 weeks spironolactone or finerenone should be increased to 40mg qd and electrolytes should be reviewed at 2 weeks after dosed
If the self-measured blood pressure of patients at home continues to be greater than 14090 mmHg at 2-4 weeks spironolactone or finerenone should be increased to 40mg qd and electrolytes should be reviewed at 2 weeks after dosed
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?:
None